NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)
Zolbetuximab + mFOLFOX6 as first-line treatment for patients with claudin-18.2+ / HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
This October, we are recognizing Breast Cancer Awareness Month with three very different takes on breast cancer from our organization and the Tigers who make us who we are.
Phase III study ofcabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) inpreviously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediateor poor risk (COSMIC-313)
Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) inpatients with HR+/HER2- metastatic breast cancer.
Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study.
Osimertinib as adjuvant therapy in patients(pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Tune into the discussion among top KOLs around Melanoma data presented at this year's ESMO virtual congress.
Tune into the discussion among top KOLs around GU data presented at this year's ESMO virtual congress.
Watch KOL Insights on Abstracts released during the IASLC 2021 World Conference on Lung Cancer.
Get to know the Tigers that make up each of LARVOL's dedicated teams.
What makes an “observation” an “insight” in the world of Medical Affairs? This is the question tackled by Medical Affairs professionals on this month’s Elevate podcast from the Medical Affairs Professionals Society (MAPS).
"The future of business is in the metaverse," Larvol says. "And we want to explore every angle of its use for workplace collaboration and for the future of cancer research and drug development."
What will conferences look like for MSLs throughout 2021, 2022, and beyond? And how should MSLs prepare to make the most of the changing reality?
Watch KOL Insights on GU Cancer Abstracts released during the ASCO Annual Meeting 2021
Watch KOL Insights on Cancer Abstracts released during the ASCO Annual Meeting 2021
Watch KOL Insights on Lung Cancer Abstracts released during the ASCO Annual Meeting 2021
LARVOL VIEW Top 100 is a curated list of the most influential Digital Opinion Leaders (DOLs) in oncology on Twitter. Our methodology selects and ranks DOLs based on online influence, offline activity, and the opinions of other verified oncologists.
Watch KOL Insights on Breast Cancer Abstracts released during the ASCO Annual Meeting 2021
Watch KOL Insights on DLBCL Abstracts released during the ASCO Annual Meeting 2021
CLIN's launch marks an exciting next step in the innovative work LARVOL is doing to streamline the work of oncologists and researchers
Watch KOL Insights on GI Cancer Abstracts released during the ASCO Annual Meeting 2021
Get Expert Insights on Melanoma Abstracts released during the ASCO Annual Meeting 2021
In order to get the most out of your conference attendance, you will need to have a clear plan in place.
LARVOL announces their clinical research poster, a VR-based oncologist event, and a clinical panel series during ASCO 2021
Our team of experts put together a list of the top 100 oncology conferences happening in 2021, organized in an easy-to-reference calendar view.
In our VR offices, co-workers who are thousands of miles apart can finally meet via Spatial’s 3D avatar system.
This Mother’s Day, we celebrate mothers everywhere.
Headset distribution solidifies intent to remain #1 VR-first company
Watch KOL Insights on Genitourinary Cancer Abstracts released during the AACR Annual Meeting 2021
Watch KOL Insights on Cancer Abstracts released during the AACR Annual Meeting 2021
Watch KOL Insights on Gastrointestinal Cancer Abstracts released during the AACR Annual Meeting 2021
Watch KOL Insights on Breast Cancer Abstracts released during the AACR Annual Meeting 2021
To help those interested in advocating for support for India's efforts to control the spread of COVID-19, we’ve gathered these instructions and suggested language for outreach to US Representatives and Senators.
Watch KOL Insights on Lung Cancer Abstracts released during the AACR Annual Meeting 2021
Watch KOL Insights on Hematologic Malignancies Abstracts released during the AACR Annual Meeting 2021
Curated comments and sentiment from verified oncologists empower pharma marketing, competitive intelligence, and medical affairs teams to make informed decisions
Read this blog to explore how MSLs and medical affairs can use social media to achieve professional growth and do much more
Coincides with launch of first social listening and sentiment analysis platform allowing researchers and pharma developers to tune into the cancer conversation with verified oncologists on Twitter
Our insightful infographic breaks down the challenges being faced by MSLs because of no in-person meetings with KOLs
Read this article first published on The MSL Journal to uncover tips that will help you maintain and even strengthen your relationships with KOLs with engaging virtual meetings.
Read this summary of insights from our latest webinar with the MSL Society to discuss the experience of the MSL community nearly a year to the day since the COVID-19 pandemic shut down their ability to meet with KOLs in person.
LARVOL announced the addition of Mark Lagunowich to their Executive Team. As Vice President, Global Sales, Lagunowich brings over 30 years of experience in the life science industry.
Watch a panel of experts discuss the practice-changing potential of ASCO GU 2021's top abstracts on the standard of care.
Take a deep dive into the current predictive biomarker landscape—and what the future holds.
The Covid-19 pandemic has once again brought VUCA in focus. Read our blog understand the evolving value proposition for MSLs.
Learn more about “Google for cancer” Veri and the latest technologies in the field of predictive biomarkers in our blog here.
Discover meaningful and relevant insights on KOL monitoring by MSLs in our infographic.
Read our blog to know more about the ways you can increase KOL engagement during the pandemic.
We are announcing our new brand identity to reflect a stronger, more focused, and modern representation of our team and company in several ways. Read our blog to learn more.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.
